January 31, 2015 5:35 AM ET

Healthcare Providers and Services

Company Overview of Ambry Genetics Corp.

Company Overview

Ambry Genetics Corp. provides diagnostic testing services for genetic diseases. It focuses on clinical diagnostics, such as diagnostic testing for genetic diseases; and genomic services, which include sequencing, exome sequencing, targeted enrichment, microarrays, genotyping, ADME sequencing, and bioinformatics. The company also provides genomic research services for gene expression, SNP genotyping, and sample preparation for targeted sequencing using sequencers. It serves academic institutions, and small to large pharmaceutical companies. Ambry Genetics Corp. was founded in 1999 and is based in Aliso Viejo, California.

15 Argonaut

Aliso Viejo, CA 92656

United States

Founded in 1999





Key Executives for Ambry Genetics Corp.

Interim Chief Executive Officer
Chief Medical Officer
Laboratory Director
Director of Clinical Affairs
Compensation as of Fiscal Year 2014.

Ambry Genetics Corp. Key Developments

Ambry Genetics Announces Settlement in BRCA1 and BRCA2 Gene Patent Infringement Case

Ambry Genetics announced a settlement agreement that ends the BRCA1 and BRCA2 gene patent infringement litigation against Ambry that began on July 9, 2013. The case is University of Utah Research Foundation, Ambry Genetics Corporation, United States District for the District of Utah, Case No. 2:13-cv-00640-RJS. Under this agreement the plaintiffs, including Myriad Genetics, the University of Utah Research Foundation, the Trustees of the University of Pennsylvania, HSC Research and Development LP, and Endorecherche Inc. and Ambry agree to dismiss with prejudice their respective claims and counterclaims against one another in the BRCA1 and BRCA2 genepatent infringement litigation. Additionally, the Patent Owners grant a covenant to not sue Ambry under the patents asserted in the litigation proceedings. The decision to settle occurs after the United States Court of Appeals for the Federal Circuit held on December 17, 2014 that claims from three of the patents covering DNA-based BRCA1 and BRCA2 tests Myriad was asserting against Ambry did not contain subject matter eligible for patent protection.

Ambry Genetics Publishes Data Supporting Use of Hereditary Cancer Panel Testing

Ambry Genetics announced the publication of the highly anticipated results on the first 2,000 patients tested, in the journal Genetics in Medicine, supporting the clinical adoption of multigene cancer panels in the diagnosis of hereditary cancer predisposition. The study evaluated the first 2,079 patients who underwent Ambry's hereditary cancer multigene panel testing. Tests included a comprehensive analysis of 14-22 cancer susceptibility genes based on the panel ordered (BreastNext, OvaNext, ColoNext or CancerNext). This study identified positive test results in up to 9.6% of patients, with the majority of positive results correlating with clinical histories in affected patients. Interestingly, 30% of ColoNext patients with mutations in genes with well-established diagnostic criteria did not meet clinical criteria for the corresponding hereditary condition and would have eluded diagnosis by conventional methodologies. Results from this study point to an important role for targeted multigene panels in diagnosing hereditary cancer predisposition, particularly for patients with clinical histories spanning several possible diagnoses and for patients with suspicious clinical histories not meeting diagnostic criteria for a specific hereditary cancer syndrome.

Ambry Genetics Prevails in Preliminary Injunction Motion Filed by Myriad Genetics

Ambry Genetics announced that it has defended itself against the preliminary injunction motion filed on July 9, 2013 by Myriad Genetics and other plaintiffs in University of Utah Research Foundation et al. v. Ambry Genetics Corporation, Case No. 2:13-cv-00640-RJS, pending in the United States District Court for the District of Utah. Since launching their BRCA product line on the day of the Supreme Court's ruling against Myriad (June 13, 2013), Ambry has been widely embraced by physicians, genetic counselors and other medical professionals. Given today's favorable ruling, Ambry will continue to offer all previously launched BRCA-related genetic testing products. Ambry Genetics is represented in the lawsuit by William Gaede and Eric Hagen of McDermott Will & Emery and Edgar Cataxinos of TraskBritt.

Similar Private Companies By Industry

Company Name Region
McKesson Specialty Distribution LLC United States
Allen Hospital Inc. United States
Magellan Behavioral Health of Florida, Inc. United States
12 Oaks Management Services, Inc. United States
Jackson Surgical Assistants, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Ambry Genetics Corp., please visit www.ambrygen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.